Cargando…

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma

Increases in the mean corpuscular volume (MCV) have been observed in patients with metastatic renal cell carcinoma (mRCC) on tyrosine kinase inhibitor (TKI) treatment; however, its association with progression‐free‐survival (PFS) is unknown. We aimed to characterize TKI‐associated macrocytosis in mR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourlon, Maria T., Gao, Dexiang, Trigero, Sara, Clemons, Julia E., Breaker, Kathryn, Lam, Elaine T., Flaig, Thomas W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224865/ https://www.ncbi.nlm.nih.gov/pubmed/27758076 http://dx.doi.org/10.1002/cam4.919

Ejemplares similares

Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
por: Kucharz, Jakub, et al.
Publicado: (2016)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Effects of sunitinib on endothelial dysfunction, metabolic changes, and cardiovascular risk indices in renal cell carcinoma
por: Lai, Silvia, et al.
Publicado: (2020)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Evaluation of children with macrocytosis: clinical study
por: Sarbay, Hakan, et al.
Publicado: (2018)

Macrocytosis among patients with heroin use disorder
por: Ng, Mei-Hing, et al.
Publicado: (2019)

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
por: Shinohara, N, et al.
Publicado: (2011)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma
por: Xing, Qianwei, et al.
Publicado: (2019)

Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial
por: Cella, David, et al.
Publicado: (2014)

Haematinic Deficiency and Macrocytosis in Middle-Aged and Older Adults
por: McNamee, Therese, et al.
Publicado: (2013)

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT)
por: Altoos, Basel, et al.
Publicado: (2015)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
por: Gore, M E, et al.
Publicado: (2015)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Treatment evolution for metastatic castration‐resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real‐world data
por: Flaig, Thomas W., et al.
Publicado: (2015)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
por: Zhou, Ye, et al.
Publicado: (2020)

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
por: Blagoev, Krastan B., et al.
Publicado: (2013)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

Unrecognized Prevalence of Macrocytosis among the Patients with First Episode of Psychosis and Depression
por: Ransing, Ramdas Sarjerao, et al.
Publicado: (2018)

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
por: Thompson Coon, J S, et al.
Publicado: (2009)

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
por: Ma, Lucy X., et al.
Publicado: (2020)

Clinical significance of glutamate metabotropic receptors in renal cell carcinoma risk and survival
por: Huang, Chao‐Yuan, et al.
Publicado: (2018)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma
por: Barrios, Carlos H, et al.
Publicado: (2016)

Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma
por: Lam, Elaine T., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vkjprpv5r0lobe0tsqs6piorbj